Scott Kelly is a former military fighter pilot and test pilot, an engineer, a retired astronaut, and a retired U.S. Navy captain. A veteran of four space flights, Kelly commanded the International Space Station (ISS) on three expeditions and was a member of the yearlong mission to the ISS. In October 2015, he set the record for the total accumulated number of days spent in space, the single longest space mission by an American astronaut. He lives in Houston, Texas.

Alan Lotvin, M.D., currently serves as executive vice president of CVS Health and president of CVS Caremark, the company's pharmacy benefits management (PBM) business, which provides coverage to approximately 100 million lives.

Throughout his entire career, Dr. Lotvin has been a champion of making the health care system easier to use, more affordable and convenient - creating products and solutions that keep consumers at the core of their health care. He brings this discipline to the PBM business along with CVS Health's efforts to apply advanced technologies to the treatment of end stage renal disease.

As a cardiologist, Dr. Lotvin brings clinical expertise and practical insights on how to improve health care and accelerate innovation. He is an inventor of a percutaneous device to repair one of the valves in the heart and has a long standing interest in the use of advanced analytics and machine learning in health care, starting with a degree in Medical Informatics from Columbia University.

Dr. Lotvin - also a helicopter pilot - currently resides outside of Boston, MA and is actively involved in his community. He is a passionate and committed advocate for social justice, racial and gender equality and an empowered democracy.

Sekou Andrews is the Founder/CEO of SekouWorld, Inc., innovator of "poetic voice" and one of the most successful spoken word poets in the world. On any given day, this school-teacher turned artist and entrepreneur, who built a 7-figure company on poetry, can be found keynoting at a Fortune 500 company, inspiring thousands at a concert, or performing for Barack Obama in Oprah's backyard. Sekou is the creator of "poetic voice" - a cutting-edge speaking category that seamlessly fuses inspirational speaking with spoken word poetry, like "Hamilton" meets "TED". This innovative blend of strategic storytelling, thought leadership, spoken word, theater and comedy humanizes content, making it entertaining, moving and memorable. Sekou's accomplishments include two National Poetry Slam championships, two national poetry tours, two Independent Music Awards, three Helen Hayes Awards, the most "Just Plain Folks" music awards in history, the 2020 ABA "Entrepreneur of the Year" award, and the first "Best Spoken Word Album" Grammy nomination for a poet in 30 years.

It is no surprise that Forbes has called Sekou a "polymath" and "the de facto poet laureate of corporate America." His "wow-factor" is in high demand with the world's most successful organizations, including Google, Viacom, Toyota, Nike, Cisco, Linkedin, Capital One, L'Oreal, Global Green, Paypal, ASAE, The Gap, Paypal, General Mills, the ACLU, and the NBA to name but a few. Sekou's work has also been featured on such diverse national media outlets as ABC World News, CBS, MSNBC, HBO, Good Morning America, Showtime, MTV and BET, and he has given private performances for such prominent individuals as Maya Angelou, Quincy Jones, Larry King, Hillary Clinton, Norman Lear, Sean "Diddy" Combs, and Coretta Scott King. Sekou has also emerged as a powerful voice for health and wellness, routinely evoking tears, cheers, and standing ovations at events for clients such as the Johnson & Johnson, United Healthcare, Mayo Clinic, Blue Shield, Kaiser Permanente, TEDMED, Roche, Northwell Health, Genentech, and the American Medical Association.

Dr. Taylor is a dynamic innovator, scientist and entrepreneur and a global thought leader in regenerative medicine. She has published over 180 papers, holds over 30 patents, and is the founder of multiple companies. She has trained hundreds of undergraduate, graduate, and post-graduate fellows worldwide in her laboratories in the U.S. and Europe. Although she has held academic positions for over 20 years, she recently founded RegenMedix Consulting LLC to enable academic and commercial enterprises in the regenerative medicine space.

Taylor is credited with the first functional scientific repair of injured heart with stem cells in 1998. Her group further transformed the field of organ transplantation science in 2008 by developing a unique cell removal (decellularization) method that makes un-transplantable organs into usable scaffold frameworks for building new organs with stem cells. This was so revolutionary it was recognized as one of the "Top 10 Research Advances" by the American Heart Association and Taylor was nominated as one of "100 most influential people in the world" by Time magazine. Next she turned to disease prevention and has begun to develop "cellular signatures" of heart disease and aging that appear to differ by sex race and ethnicity.

Dr. Taylor frequently appears as an expert on cell therapy, women's health, cardiac repair and organ transplantation in the public media. Her work has been recognized and featured by 60 Minutes, CNN, The New York Times, The Wall Street Journal, Forbes, Natonal Geographic, BBC Horizon, BBC News Health, ABC, NBC and CBS News, Associated Press, Good Morning America, , the Oprah Winfrey Show, NOVA Science Now, PBS NOVA Transplanting Hope, Discovery Channel's Through the Worm Hole with Morgan Freeman, Science Channel's Stem Cell Universe with Stephen Hawking, NPR's On Being with Krista Tippet and most other worldwide media outlets.

Taylor sits on numerous think tanks and international scientific committees including for the NIH, the FDA, the American Association of Blood Banks, and the Alliance for Regenerative Medicine. She is a member of the Leadership Advisory Committee for the Alliance for Regenerative Manufacturing Institute (ARMI) and sits on the international jury for the Institut de France LeFoulon-Delalande Foundation Grand Prix which is awarded annually to individuals making worldwide contributions to cardiovascular medicine.

Dr. Taylor earned a B.S. from Mississippi University for Women (MUW) and a Ph.D. from UT Southwestern Medical Center. She is appointed as a Fellow of the American Heart Association, American College of Cardiology, and European Society for Cardiology. She was awarded an honorary Doctor of Science degree by MUW and the national Distinguished Alumnus Award by the American Association of State Colleges and Universities. In 2019 she was elected as a Senior member of the National Academy of Inventors and in 2020, was nominated as a fellow to the American Institute for Medical and Biological Engineering.

Her motto is, "Build the Future of Medicine Today."

Dr. Christopher Mason is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction. He also holds appointments at the Tri-I Program on Computational Biology and Medicine (Cornell, Memorial Sloan Kettering Cancer Center and Rockefeller University), Harvard Medical School, and Yale Law School.

The Mason laboratory develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and physiology. We create and deploy novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. We also work closely with NIST/FDA to build international standards for these methods (SEQC2, IMMSA, and Epigenomics QC groups), to ensure clinical-quality genome measurements and editing. We also work with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which help establish the molecular foundations and genetic defenses for enabling long-term human spaceflight.

He has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award. He was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y. He has over 200 peer-reviewed papers and scholarly works that have been featured on the covers of Nature, Science, Cell, Nature Biotechnology, Nature Microbiology, and Neuron, as well as legal briefs cited by the U.S. District Court and U.S. Supreme Court. Coverage of his work has also appeared on the covers of the Wall Street Journal, New York Times, TIME, The LA Times, and across many media (ABC, NBC, CBS, Fox, CNN, PBS, NASA, NatGeo). He is an inventor on four patents, co-founded five biotechnology start-up companies, and serves as an advisor to many others. He lives with his daughter and wife in Brooklyn, NY.

Dr. Christopher Mason's background and appointments:

• B.S. in Genetics, University of Wisconsin-Madison (2001)
• B.S. in Biochemistry, University of Wisconsin-Madison (2001)
• Ph.D. in Genetics, Yale University (2006)
• Post-doc, Clinical Genetics, Yale Medical School (2009)
• Fellowship of Genomics, Ethics, and Law, Yale Law School (2009)
• Assistant Professor, Weill Cornell Medicine (2009)
• Associate Professor, Weill Cornell Medicine (2015)
• Director, the WorldQuant Initiative for Quantitative Prediction (2017)
• Appointments at the Tri-Institutional Program on Computational Biology and Medicine between Cornell, Memorial Sloan-Kettering Cancer Center and Rockefeller University, the Sandra and Edward Meyer Cancer Center, and the Feil Family Brain and Mind Research Institute.

Martine Rothblatt is the Chairman & CEO of United Therapeutics Corporation (UT). She started UT to save her youngest child's life from a rare illness after having previously created SiriusXM satellite radio and other satellite communications systems. She is also responsible for several innovations in aviation and architecture, including holding the Guinness Record for longest flight in an electric helicopter and creating the world's largest zero carbon footprint building. Her company is now saving hundreds of lives a year with medicines for pulmonary hypertension and neuroblastoma, and by manufacturing transplantable lungs out of rejected donor lungs. From October 2021 through January 2022 her company produced the world's first life-saving xenoheart and the first xenokidneys transplanted into humans. UT is also in pre-clinical development of manufactured kidneys, hearts and 3D printed autologous lungs to be delivered via autonomously flown electric vertical takeoff and landing (eVTOL) systems. Dr. Rothblatt earned her Ph.D. in Medical Ethics from the Royal London College of Medicine and Dentistry after earning JD and MBA degrees from UCLA, which also recently awarded her the UCLA Medal, its highest honor. She is an inventor on several patents and the author of several books, the most recent of which pertain to artificial cognition and cyber-consciousness.

Dr. Fauci was appointed director of NIAID in 1984. He oversees an extensive portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis and malaria as well as emerging diseases such as Ebola and Zika. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. The NIAID budget for fiscal year 2020 is an estimated $5.9 billion.

Dr. Fauci has advised six presidents on HIV/AIDS and many other domestic and global health issues. He was one of the principal architects of the President's Emergency Plan for AIDS Relief (PEPFAR), a program that has saved millions of lives throughout the developing world.

Dr. Fauci also is the longtime chief of the Laboratory of Immunoregulation. He has made many contributions to basic and clinical research on the pathogenesis and treatment of immune-mediated and infectious diseases. He helped pioneer the field of human immunoregulation by making important basic scientific observations that underpin the current understanding of the regulation of the human immune response. In addition, Dr. Fauci is widely recognized for delineating the precise ways that immunosuppressive agents modulate the human immune response. He developed effective therapies for formerly fatal inflammatory and immune-mediated diseases such as polyarteritis nodosa, granulomatosis with polyangiitis (formerly Wegener's granulomatosis), and lymphomatoid granulomatosis. A 1985 Stanford University Arthritis Center Survey of the American Rheumatism Association membership ranked Dr. Fauci's work on the treatment of polyarteritis nodosa and granulomatosis with polyangiitis among the most important advances in patient management in rheumatology over the previous 20 years.

Dr. Fauci has made seminal contributions to the understanding of how HIV destroys the body's defenses leading to its susceptibility to deadly infections. Further, he has been instrumental in developing treatments that enable people with HIV to live long and active lives. He continues to devote much of his research to the immunopathogenic mechanisms of HIV infection and the scope of the body's immune responses to HIV.

In a 2020 analysis of Google Scholar citations, Dr. Fauci ranked as the 41st most highly cited researcher of all time. According to the Web of Science, he ranked 8th out of more than 2.2 million authors in the field of immunology by total citation count between 1980 and January 2020.

Dr. Fauci has delivered major lectures all over the world and is the recipient of numerous prestigious awards, including the Presidential Medal of Freedom (the highest honor given to a civilian by the President of the United States), the National Medal of Science, the George M. Kober Medal of the Association of American Physicians, the Mary Woodard Lasker Award for Public Service, the Albany Medical Center Prize in Medicine and Biomedical Research, the Robert Koch Gold Medal, the Prince Mahidol Award, and the Canada Gairdner Global Health Award. He also has received 45 honorary doctoral degrees from universities in the United States and abroad.

Dr. Fauci is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society, as well as other professional societies including the American College of Physicians, the American Society for Clinical Investigation, the Association of American Physicians, the Infectious Diseases Society of America, the American Association of Immunologists, and the American Academy of Allergy, Asthma & Immunology. He serves on the editorial boards of many scientific journals; as an editor of Harrison's Principles of Internal Medicine; and as author, coauthor, or editor of more than 1,300 scientific publications, including several textbooks.

Patrice A. Harris, MD, MA, a psychiatrist from Atlanta, became the 174th president of the American Medical Association in June 2019, and the organization's first African-American woman to hold this position. Dr. Harris has diverse experience as a private practicing physician, public health administrator, patient advocate and medical society lobbyist.

Dr. Harris currently spearheads the AMA's efforts to end the opioid epidemic and has been chair of the AMA Opioid Task Force since its inception in 2014. During her presidency, Dr. Harris will continue to lead the task force as it works across every state to eliminate barriers to treatment, provide patients with access to affordable, non-opioid pain care, and fight the stigma faced by those with substance use-disorders.

Having served on the AMA Board of Trustees since 2011, and as chair from 2016 to 2017, she has long been a mentor, a role model and an advocate. Prior to serving on the board, Dr. Harris honed her broad knowledge and deep understanding of health care issues through various leadership roles. At the AMA these included having served for many years on the AMA Council on Legislation, including a term as chair, and on multiple AMA task forces on topics such as health information technology, payment and delivery reform, and private contracting. Beyond the AMA she has held positions of leadership with the American Psychiatric Association, the Georgia Psychiatric Physicians Association, the Medical Association of Georgia, and The Big Cities Health Coalition, where she chaired this forum composed of leaders from America's largest metropolitan health departments.

Growing up in Bluefield, West Virginia, Dr. Harris dreamt of entering medicine at a time when few women of color were encouraged to become physicians. Dr. Harris spent her formative years at West Virginia University, earning a BA in psychology, an MA in counseling psychology and, ultimately, a medical degree in 1992. It was during this time that her passion for helping children emerged, and she completed her psychiatry residency and fellowships in child and adolescent psychiatry and forensic psychiatry at the Emory University School of Medicine.

Two themes that govern Dr. Harris's professional life are a passion to improve the lives of children and service

to others. A recognized expert in children's mental health and childhood trauma, Dr. Harris has led efforts on both local and national levels to integrate public health, behavioral health and primary care services with supports for employment, housing and education.

A distinguished fellow of the American Psychiatric Association, Dr. Harris continues in private practice and currently consults with both public and private organizations on health service delivery and emerging trends in practice and health policy. She is an adjunct assistant professor in the Emory Department of Psychiatry and Behavioral Sciences, and an adjunct clinical assistant professor in psychiatry and behavioral sciences at Morehouse School of Medicine.

Dean Kamen is an inventor, an entrepreneur, and a tireless advocate for science and technology. His roles as inventor and advocate are intertwined—his own passion for technology and its practical uses has driven his personal determination to spread the word about technology's virtues and by so doing to change the culture of the United States.

As an inventor, he holds more than 1000 U.S. and foreign patents, many of them for innovative medical devices that have expanded the frontiers of health care worldwide. While still a college undergraduate, he invented the first wearable infusion pump, which rapidly gained acceptance from such diverse medical specialties as oncology, neonatology, and endocrinology. In 1976, he founded his first medical device company, AutoSyringe, Inc., to manufacture and market the pumps. Then, working with leading diabetes researchers, Dean pioneered the design and adoption of the first portable insulin pump. It was quickly demonstrated that using a pump could much more effectively control patients' blood glucose levels. . At age 30, he sold AutoSyringe to Baxter Healthcare Corporation.

Following the sale of AutoSyringe, Inc., he founded DEKA Research & Development Corporation to develop internally generated inventions as well as to provide research and development for major corporate clients. Kamen led DEKA's development of the HomeChoiceTM peritoneal dialysis system for Baxter International Inc. The HomeChoiceTM system allows patients to be dialyzed in the privacy and comfort of their home and quickly became the worldwide market leader. Kamen also led the development of technology to improve slide preparation for the CYTYC (now Hologic Inc.) ThinPrep® Pap Test. Kamen-led DEKA teams have also developed critical components of the UVARTM XTSTM System, an extracorporeal photophereisis device marketed by Therakos, a unit of Johnson & Johnson, for treatment of T-Cell lymphoma. An advanced prosthetic arm in development for DARPA should advance the quality of life for returning injured soldiers. Other notable developments include the HydroflexTM surgical irrigation pump for C.R. Bard, the CrownTM stent, an improvement to the original Palmaz-Schatz stent, for Johnson & Johnson, the iBOTTM mobility device, and the Segway® Human Transporter.

Kamen has received many awards for his efforts. Notably, Kamen was awarded the National Medal of Technology in 2000. Presented by President Clinton, this award was in recognition for inventions that have advanced medical care worldwide, and for innovative and imaginative leadership in awakening America to the excitement of science and technology. Kamen was elected a member of the National Academy of Engineering in 1997. He was awarded the Lemelson-MIT Prize in 2002, and was inducted into the National Inventors Hall of Fame in May 2005. He is a Fellow of the American Institute for Medical & Biological Engineering, as well as many other national and international engineering organizations.

In addition to DEKA, one of Dean's proudest accomplishments is founding both FIRST® (For Inspiration and Recognition of Science and Technology) and FIRST® Global, organizations dedicated to motivating the next generation to understand, use and enjoy science and technology.

Kimbal Musk is chef, restauranteur, and philanthropist. His personal mission is to pursue an America where everyone has access to real food. Mr. Musk has been named a Global Social Entrepreneur by the World Economic Forum. He is the Co-Founder and Executive Chairman of three businesses - The Kitchen Restaurant Group, Big Green, and Square Roots - with real food missions that are rapidly scaling across the United States.

The Kitchen Restaurant Group -- with its three concepts Next Door, Hedge Row, and The Kitchen -- serves real food at every price point and has created over a thousand mission driven jobs. The restaurants source sustainably grown food from American farmers, stimulating the local farm economy to the tune of millions of dollars a year. Mr. Musk's non-profit organization, Big Green, builds permanent, outdoor Learning Garden classrooms in hundreds of underserved schools across America reaching over 350,000 students everyday. His tech-enabled food company, Square Roots, builds urban farms in climate-controlled shipping containers with the mission to bring real food to people in cities around the world by empowering next-gen farmers.

Mr. Musk is on the board for Tesla and SpaceX. Follow him on Twitter @Kimbal and Instagram @KimbalMusk.

Arianna Huffington is the founder and CEO of Thrive, the founder of The Huffington Post, and the author of 15 books, including Thrive and The Sleep Revolution. In 2016, she launched Thrive, a leading behavior change tech company with the mission of changing the way we work and live by ending the collective delusion that burnout is the price we must pay for success. She has been named to Time Magazine's list of the world's 100 most influential people and the Forbes Most Powerful Women list. Originally from Greece, she moved to England when she was 16 and graduated from Cambridge University with an M.A. in economics. At 21, she became president of the famed debating society, the Cambridge Union. She serves on numerous boards, including Onex and The B Team. Her last two books, Thrive: The Third Metric to Redefining Success and Creating a Life of Well-Being, Wisdom, and Wonder and The Sleep Revolution: Transforming Your Life, One Night At A Time, both became instant international bestsellers. Most recently, she wrote the foreword to Thrive's first book, Your Time to Thrive: End Burnout, Increase Well-being, and Unlock Your Full Potential with the New Science of Microsteps.

Nicole Shanahan is a California based attorney and the founder and president of Bia-Echo Foundation, a private foundation that aims to invest in changemakers at the forefront of innovation who are tackling some of the world's greatest challenges: reproductive longevity & equality, criminal justice reform and a healthy & livable planet. Initial investments and projects led by Bia-Echo include, the launch of the world's first Center for Reproductive Longevity and Equality at the Buck Institute for Research on Aging and the Stanford Computational Policy Lab to drive social impact on criminal justice reform via data analysis and technical innovation. Prior to launching Bia-Echo, Nicole supported these efforts through the Sergey Brin Family Foundation.

Nicole is also the founder and chair of the Board of ClearAccessIP, an integrated patent management company using AI to help the creators and owners of IP assets effectively develop, manage and transact patent-protected technology. Nicole is a research fellow at CodeX, the Stanford Center of Legal Informatics, a joint center between Stanford Law School and Computer Science, where she launched the Smart Prosecution project, a multi-disciplinary effort applying data science to the prosecutorial process, involving partnerships with district attorneys and community organizations. Apart from the practical applications of legal technology, her academic research centers on an extension of Ronald Coase's work on transaction cost theory. Entitled, "Coasean Mapping" she theorizes on the pace and nature of society's adoption of artificial intelligence for law and government.

Nicole is a graduate of Santa Clara University Law School and the University of Puget Sound. She currently resides in the San Francisco Bay Area with her family.

Dr. Larry Brilliant is a physician and epidemiologist, CEO of Pandefense Advisory, and Chair of the Advisory Board of the NGO Ending Pandemics. He is also a senior advisor to Jeff Skoll and serves on the board of the Skoll Foundation. Dr. Brilliant was previously the president and CEO of the Skoll Global Threats Fund, vice president of Google, and the founding executive director of Google.org. He also co-founded the Seva Foundation, an NGO whose programs have given back sight to more than 5 million blind people in two dozen countries. In addition, he co-founded The Well, a progenitor of today's social media platforms. Earlier in his career, Dr. Brilliant was an associate professor of epidemiology and international health planning at the University of Michigan. Dr. Brilliant lived in India for nearly a decade where he was a key member of the successful WHO Smallpox Eradication Programme for SE Asia as well as the WHO Polio Eradication Programme. More recently, he was chairman of the National Biosurveillance Advisory Committee, which was created by presidential directive of President George W. Bush, he was a member of the World Economic Forum's Agenda Council on Catastrophic Risk, and a "First Responder" for CDC's bio-terrorism response effort. Recent awards include the TED Prize, Time magazine's 100 Most Influential People, "International Public Health Hero" and four honorary doctorates. He has lectured at Oxford, Harvard, Berkeley and many other colleges, spoken at the Royal Society, the Pentagon, NIH, the United Nations, and some of the largest companies and nonprofits all over the world. He has written for Forbes, the Wall Street Journal, the Guardian, and other magazines and peer reviewed journals and was part of the Global Business Network where he learned scenario planning. Dr. Brilliant is the author of "Sometimes Brilliant" a memoir about working to eradicate smallpox, and a guide to managing vaccination programs entitled "The Management of Smallpox Eradication."

Norman Lear is a television and film writer/producer whose dynamic career in Hollywood has encompassed both the Golden Age and Streaming Era. At 98, Norman Lear has no plans to retire.

His production banner, ACT III, has a first look deal with Sony Pictures Television. He serves as executive producer to the critically acclaimed reimagining of One Day At A Time, which was resurrected for a fourth season by PopTV and airing on CBS, Mondays beginning October 5th. He executive produces and co-hosts LIVE In Front of a Studio Audience…, alongside Jimmy Kimmel. The series set record ratings for ABC and won the Emmy for Outstanding Variety Special for two consecutive years. In addition to the soon to be released feature I Carry You With Me, Lear will also be Executive Producing a reimagining of Good Times - animated --coming to Netflix in 2021.

Lear's social and political activism extend beyond the messaging of his programs and he continues to be a strong advocate for civic duty, and progressive American values.

Born in 1922 in New Haven, Connecticut, Lear attended Emerson College before flying 52 combat missions over Europe during World War II. Upon his return, Norman began a successful career writing and producing programs like The Colgate Comedy Hour, and The Martha Raye Show -- ultimately leading to Lear captivating 120 million viewers per week with his iconic shows of the 1970s and '80s — All in the Family, Good Times, The Jeffersons, Maude, and Mary Hartman.

As Lear began witnessing the rise of the radical religious right, he put his television career on hold in 1980 to found People For The American Way. Today, the organization is over one million members and activists strong and continues to fight right-wing extremism while defending constitutional values like free expression, religious liberty, equal justice under the law, and the right to meaningfully participate in our democracy.

Lear is a 2017 Kennedy Center Honoree; a recipient of the National Medal of Arts in 1999, the Peabody Lifetime Achievement Award in 2016; and a proud member of the inaugural group of inductees to the Television Academy Hall of Fame in 1984. He has won six Primetime Emmys and a Golden Globe.

Norman Lear is a father to six, a grandfather to four, and the husband of Lyn Davis Lear.

Dr. Kizzmekia S. Corbett is an assistant professor of immunology and infectious diseases at Harvard's T.H. Chan School of Public Health, Shutzer Assistant Professor at Harvard's Radcliffe Institute of Advanced Study, and Associate Member of the Phillip T. and Susan M. Ragon Institute. Dr. Corbett's laboratory studies host immune responses to coronaviruses and other emerging and re-emerging viruses to propel novel vaccine and antibody therapy development. In 2008, she received a BS in Biological Sciences, with a secondary major in Sociology, from the University of Maryland - Baltimore County, where she was a Meyerhoff Scholar and NIH undergraduate scholar. She then obtained her PhD in Microbiology and Immunology in 2014 from the University of North Carolina at Chapel Hill holding multiple honors, including a director's scholarship. Prior to Harvard, she was a research fellow and scientific lead at the National Institute of Allergy and Infectious Diseases Vaccine Research Center. A leading COVID-19 vaccine, mRNA-1273, was co-designed by Dr. Corbett's NIH team from viral sequence and rapidly deployed to industry partner, Moderna, Inc., for Phase 1 clinical trial, which unprecedentedly began only 66 days from viral sequence release. mRNA-1273 is a now used around the world to prevent COVID-19 disease. Alongside mRNA-1273, Dr. Corbett boasts a patent portfolio which also includes universal coronavirus and influenza vaccine concepts and novel therapeutic antibodies. In all, she has over 15 years of experience studying dengue virus, respiratory syncytial virus, influenza virus, and coronaviruses, garnering several prestigious awards and recognitions, such as being named a Time Magazine "Hero of the Year" in 2021. Combining her research goals with her knack for mentorship, Dr. Corbett invests much of her time in underserved communities as an advocator of STEM education and vaccine awareness.

Dr. Tom Frieden is a physician trained in internal medicine, infectious diseases, public health, and epidemiology. He is former director of the US Centers for Disease Control and Prevention and former commissioner of the New York City Health Department. Dr. Frieden is currently President and CEO of Resolve to Save Lives.

Dr. Frieden began his public health career in New York City confronting the largest outbreak of multi-drug resistant tuberculosis to occur in the US. He was then assigned to India, on loan from the Centers for Disease Control and Prevention, where he helped scale up a program for effective tuberculosis diagnosis, treatment, and monitoring. Asked to return to New York City to become Mayor Mike Bloomberg's Health Commissioner, he directed efforts to reduce smoking and other leading causes of death that increased life expectancy by 3 years. As Director of the US Centers for Disease Control and Prevention, Dr. Frieden oversaw the work that helped end the 2014 West Africa Ebola epidemic. He now leads Resolve to Save Lives, an initiative of the global health organization Vital Strategies, that works with countries to prevent 100 million deaths and to make the world safer from epidemics. During the Covid pandemic, Dr. Frieden has overseen an expansion of Resolve to Save Lives activities including policy and program innovations in the United States, counsel to multilateral institutions, and support for rapid response, health care worker safety, and data-driven decision-making in more than 20 countries.

Dr. Frieden is also Senior Fellow for Global Health at the Council on Foreign Relations.

Paul Stamets, speaker, author, mycologist, medical researcher and entrepreneur, is considered an intellectual and industry leader in fungi: habitat, medicinal use, and production. He lectures extensively to deepen the understanding and respect for the organisms that literally exist under every footstep taken on this path of life.

Paul is the author of six books (including Mycelium Running: How Mushrooms Can Help Save the World, Growing Gourmet & Medicinal Mushrooms, and Psilocybin Mushrooms of the World), he has discovered and named numerous new species of psilocybin mushrooms. Paul has been awarded more than 40 patents with several patent applications in queue for unexpected beneficial activity of psilocybin analogues stacked with other substances.

He has received numerous awards, including: Invention Ambassador (2014-2015) for the American Association for the Advancement of Science (AAAS), the National Mycologist Award (2014) from the North American Mycological Association (NAMA), and the Gordon & Tina Wasson Award (2015) from the Mycological Society of America (MSA). His work has entered into the mainstream of popular culture. In the new Star Trek: Discovery series on CBS, the Science Officer is portrayed by an Astromycologist.... a Lt. Paul Stamets. Paul's work with mycelium is a central theme of this series.

Christiana Musk is the founder of Flourish*ink, a platform for catalyzing conversations on the future of food and curator of food content for the Near Future Summit.

Previously, Christiana Musk was the Executive Director of Food Choice Taskforce, a focused initiative on sustainable diets and led the food system program for Avatar Alliance Foundation (both founded by filmmaker James Cameron & Suzy Amis Cameron) where she worked to protect the science behind the U.S. Dietary Guidelines. Additionally, Christiana Musk worked alongside think tank Chatham House to develop award-winning research Livestock - Climate Change's Forgotten Sector: Global Public Opinion on Meat and Dairy Consumption. Her food policy research at City University of London, which sustainably addresses the demand for animal ­sources foods: A Discourse Analysis of Public Speeches Representing Competing World Views, was awarded the British Farmer's Livery WCF Prize for best dissertation to contribute to food and farming in the UK.

Musk was a co-founder of Zaadz.com, an early online social network for people who want to change the world, which was sold to Gaiam, inc. in 2007 and a founding partner of the leading clean energy retail company in the country, Green Mountain Energy, which sold to NRG inc. in 2011. Since 2008, Musk has been an operating partner at Satori Capital and serves on the board of Unreasonable Group, an accelerator for entrepreneurs offering solutions to global challenges. Musk has also been writing about sustainability, clean tech, and food issues for the Huffington Post since 2006, contributes to the World Positive, and Future of Food platforms on Medium and has worked on or advised several documentaries and their social action campaigns, including Leonardo di Caprio's The 11th Hour, as well as Racing Extinction, and Game Changers.

A sought-after public speaker, she has presented to audiences around the world from the United Nations to the Aspen Ideas Festival, the EAT Forum, and Summit Series. Christiana Musk's unique perspective has landed her on the cover of Kiplinger's and inside The New York Times, C Magazine, the Dallas Morning News, and The Herald Tribune, among others.

Christiana lives in Boulder Colorado with food entrepreneur Kimbal Musk, founder of The Kitchen Restaurant Group, urban farm incubator Square Roots, and Big Green—the largest learning garden non-profit in the world. He serves on the boards of SpaceX, and Tesla. They have four delightful children and enjoy cooking and hiking and singing Johnny Cash duets together.

Dr. Iya Khalil is a technology entrepreneur and physicist with a vision of transforming medicine and healthcare into a discipline that is quantitative, predictive, and patient-centric via AI and big data. Recognized by President Obama at a White House dinner as a leading entrepreneur in genomic medicine, she has co-founded two AI and machine learning companies: Gene Network Sciences Inc. and GNS Healthcare. Dr. Khalil is the co-inventor of the proprietary AI and machine learning software platform that underpins both entities. Her machine learning and AI expertise spans 20 years with applications in drug discovery, drug development, clinical trial optimization, real world evidence and pharmaceutical commercial applications, and treatment algorithms that can be applied at the point of care. Dr. Khalil has published and presented extensively in AI and machine learning for healthcare, including peer-reviewed journal articles and poster presentations at scientific conferences such as ASCO, AACR, ASH, ISPOR and EASL.

She was directly responsible for accelerating the launch of the GNS' pharmaceutical and precision medicine business, well before machine learning and AI was recognized by pharma as a key strategic need. She excels at commercializing complex and impactful technologies, having launched several successful collaborations with major pharmaceutical companies including Roche, Sanofi, Gilead, Novartis, Pfizer, Celgene with major foundations and providers including MMRF, CHDI, Dana Farber, and Providence Swedish, as well as between pharmaceutical companies and payers to enable value-based reimbursement models.

In 2018, Dr. Khalil was named one of Inc. magazine's list of top female founders. In 2019, she was among Forbes top women-led startups that are "crushing tech" and was profiled as one of the women making artificial intelligence more accessible and less scary. She also was named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry for her abilities to build bridges across the life science and healthcare industries, bringing people together to harness the power of computational modeling to change the lives of patients. She is a frequent speaker at industry conferences including Exponential Medicine, Milken Global Conference, Health 2.0, SXSW, Bio, and TEDX.

Dr. Khalil serves as an advisor to the Bill and Melinda Gates Foundation, is on the board of the Accelerated Cure Project, the Scientific Advisory Board of Biocentury Innovations, the Advisory Board of the Convergence Forum, and the Board of Advisors of Life Sciences Cares. Recently, she was appointed to the Massachusetts Center for Health Information and Analysis (CHIA) Oversight Council by Governor Baker.

Iya received her PhD and MS in Physics from Cornell University. In her spare time, she loves to advise early startups, spend time with her family and friends, travel, cook Libyan cuisine, and enjoy the outdoors. She is also fluent in Arabic. She is a passionate member of Springboard enterprises, the largest network of innovators, investors and influencers who are dedicated to building high-growth women led technology companies.

David A. Sinclair, Ph.D. is a New York Times bestselling author and a tenured Professor of Genetics, Harvard Medical School. He is best known for his work on genes and small molecules that delay aging, including the Sirtuin genes, resveratrol and NAD precursors. He has published over 200 scientific papers, is a co-inventor on over 50 patent and patent applications, and has co-founded a dozen biotechnology companies in the areas of aging, vaccines, diabetes, fertility, cancer, and biodefense. His book Lifespan: Why We Age and Why We Don't Have To was published in September 2019 by Simon and Schuster. He serves as co-chief editor of the scientific journal Aging, works with national defense agencies and with NASA and has received 35 honors including being one of Australia's leading scientists under 45, the Australian Medical Research Medal, the NIH Director's Pioneer award, TIME magazine's list of the "100 most influential people in the world" (2014) and the "Top 50 people in Healthcare." (2018). In 2018, he became an Officer of the Order of Australia for his work in medicine and national security.

Dr. Strathdee is an infectious disease epidemiologist who is Associate Dean of Global Health Sciences and Harold Simon Professor of Medicine at the University of California San Diego where she codirects the Center for Innovative Phage Applications and Therapeutics (IPATH). Strathdee was recently credited with saving her husband's life from a deadly superbug infection using bacteriophages -viruses that attack bacteria. The case, which involved cooperation from three universities, the U.S. Navy and researchers across the globe, shows how phage therapy is a future weapon against multi-drug resistant bacterial infections which are expected to kill 10 million people per year by 2050. Strathdee and Patterson co-authored a book on their story called The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug. For her efforts to revitalize phage therapy in the West, she was named one of TIME magazine's Most Influential People in Health Care in 2018.

Goldie Hawn is an Academy Award winning actress, producer, director, best-selling author and true children's advocate. She is the Founder of The Goldie Hawn Foundation, a public charity with a mission to equip children with the social and emotional skills they need to lead smarter, healthier, happier and ultimately more productive lives.

Alarmed by increases in school violence, youth depression and suicide, and the persistent failure of the education system to help children cope with increasingly stressful lives, Hawn started her Foundation in 2003, applying cutting edge scientific research to create education programs that support the social and emotional development of children. Working with leading neuroscientists, educators, psychologists and researchers, the Foundation developed MindUP™ an evidence-based curriculum and teaching model for grades K-12 that provide tools to help children self-regulate and understand their own emotions, moods and behaviors; reduce stress and anxiety; sharpen concentration; increase empathy; and improve academic performance.

MindUP™ is the signature program of The Goldie Hawn Foundation which is serving over six million children in the US, Canada, UK, Finland, Ireland, Greece, Venezuela, Uganda, Portugal, Serbia, Jordan, Hong Kong, Australia, and New Zealand. The skills and mindfulness practices that are being taught have helped children improve learning and academic performance and learn valuable social and emotional skills that build personal resilience for a lifetime.

Hawn authored two best-selling books, a memoir "A Lotus Grows in the Mud", in 2005 and in 2011, "10 Mindful Minutes", offering guidance on raising healthy, joyful and resilient children. In 2015, Hawn released "10 Mindful Minutes: A Journal", a practical application to her last book, offering prompts and exercises to enhance the reader's daily life through mindfulness practice.

Goldie has lived with her partner Kurt Russell for over 30 years and has four grown children, Oliver and Kate Hudson, Wyatt Russell and stepson Boston Russell. They have also been blessed with six grandchildren. Hawn believes "children light the path to joy" and dedicated much of her life's work to creating innovative solutions to help children thrive.

Geoff Martha is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman & CEO, Geoff leads the $30 billion company and its 90,000 employees in pursuit of fulfilling the Medtronic Mission to use technology to improve human welfare. He is recognized as a driven and innovative executive — ranking in Modern Healthcare's 100 Most Influential People in Healthcare in 2020 and listed as the #1 CEO in healthcare technology by the Healthcare Technology Report in 2021.

Geoff became CEO in April 2020. Under his leadership, Medtronic is putting the 'tech' in medtech, leveraging the latest advances in cutting edge technology to transform healthcare. FORTUNE Magazine named Medtronic among the top 15 companies for its 2020 "Change the World" list, recognizing its swift efforts during the pandemic, and listed the company on its list of Most Admired Companies in 2021 and 2022.

Geoff joined Medtronic in 2011, and notably led the acquisition and integration of Covidien, the largest acquisition in the medical technology industry. Before joining Medtronic, Geoff spent 19 years at GE Healthcare and GE Capital.

Geoff is a member of the Business Roundtable, the Business Council and the World Economic Forum's International Business Council. He also serves as a member of the Executive Committee of the board of directors for the Minnesota Business Partnership. In 2021, he served as co-chair for the Taskforce on Health and Life Sciences for B20, a G20 engagement group.

An ardent supporter of philanthropic and diversity initiatives, Geoff serves on the Board of Trustees for the Asia Society and is a member of the Board of Directors for the Medtronic Foundation, Children's HeartLink, and the Northside Achievement Zone. He is also part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans and serves as Medtronic's Executive Sponsor to FIRST Robotics.

Geoff received a bachelor's degree in Finance from Pennsylvania State University, where he currently serves on the Development Council for its College of Liberal Arts. He was also captain of the Penn State men's hockey team and later inducted into its Hockey Hall of Fame.

Follow him on Twitter (@GeoffMartha) and LinkedIn (linkedin.com/in/geoff-martha).

Riccardo Sabatini is a world renown scientist and entrepreneur specialized in numerical modeling of complex system, ranging from material science, financial markets, computational genomics and drug design.

Active supporter of high impact projects, he's co-founder of the Refugees Action HUB center at MIT, educational effort of MIT targeting displaced population around the world; board member of the Fondazione ENI Enrico Mattei; member of the advisory board at ENI Next, deep-tech venture fund based in Boston; expert member of the Global Partnership on Artificial Intelligence, OECD multistakeholder initiative to guide the responsible development and use of AI; angel investor and BoA of leading startups working in AI.

In the past he's been chairman of the I7/G7 for artificial intelligence; founding member of Aiida and Quantum ESPRESSO, the largest open source suite for quantum modeling of materials; lead research scientist for Human Longevity, Silicon Valley unicorn working at the intersection of genomics and artificial intelligence.

Speaker at international events and conferences, including TED and WEF. Author in top ranking scientific journals, consultant for Fortune500 companies, inventor of several patents in biotech and IT, angel investor and board member for some groundbreaking startups in the field of artificial intelligence.

Today he's working on breakthrough approaches to programmable biology with a stellar team of likeminded scientist at Orionis Biosciences.

Dr. Jepsen is the CEO and Founder of Openwater, a company creating MRI-quality medical imaging at 1000x lower price.

Previously she was an engineering executive at Facebook, Oculus, Google, and Intel. She has designed and shipped billions of dollars worth of consumer electronics at the edge of what physics allows.

She has also founded four startups, including One Laptop per Child where she was CTO, chief architect, and delivered to mass production the $100 laptop. She was a professor at MIT and is an inventor of over 250 published or issued patents.

She has been recognized with many awards including TIME magazine's "Time 100" as one of the 100 most influential people in the world, as a CNN top 10 thinker, and in the Forbes 2018 inaugural listing of the Top 50 Women in Tech.

Dr. Rudolph Tanzi is the Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, Co-Director of the Henry and Allison McCance Center for Brain Health, and Co-Director of the MassGeneral Institute for Neurodegenerative Disease at Massachusetts General Hospital. He also serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr. Tanzi received his B.S. (microbiology) and B.A. (history) at the University of Rochester in 1980 and his Ph.D. (neurobiology) at Harvard Medical School in 1990.

Dr. Tanzi discovered the first Alzheimer's disease (AD) gene, the amyloid precursor protein (APP) gene, and co-discovered the two other early-onset familial AD genes, presenilin 1 and 2. As leader of the Cure Alzheimer's Fund Alzheimer's Genome Project, Dr. Tanzi identified several other AD genes, including ADAM10 and CD33, the first AD gene shown to regulate neuroinflammation. He also discovered the Wilson's disease gene and contributed to the discovery of several other neurological disease genes.

Dr. Tanzi's team was the first to use human stem cells to create three-dimensional cell culture organoids of AD, dubbed "Alzheimer's-in-a-Dish". This model was the first to recapitulate all three key AD pathological hallmarks in vitro, and first to definitively show that amyloid plaques directly cause neurofibrillary tangles. The 3-D model also made drug screening for AD faster and more cost-effective. Using this system, Dr. Tanzi has developed several novel therapies for AD including gamma secretase modulators targeting amyloid pathology, ALZT-OP1 targeting neuroinflammation and a neuroprotective drug combination, AMX0035, which was successful in a clinical trial of ALS. Dr. Tanzi also discovered that beta-amyloid plays a functional role in the brain as an anti-microbial peptide, supporting a role for infection in AD pathology.

Dr. Tanzi serves as Chair of the Cure Alzheimer's Fund Research Leadership Group and numerous advisory and editorial boards, He has published roughly 600 research papers and has received the highest awards in his field, including the Metropolitan Life Foundation Award, Potamkin Prize, Ronald Reagan Award, Silver Innovator Award, the Smithsonian American Ingenuity Award, and the Brain Research Foundation Award. In 2015, he was named to TIME magazine's list of TIME100 Most Influential People in the World. He co-authored the books Decoding Darkness, and the three international bestsellers, Super Brain, Super Genes, and The Healing Self, with Dr. Deepak Chopra. Dr. Tanzi has hosted three shows public television, regularly appears on television news programs, has testified to Congress on both Alzheimer's disease and brain health, and on occasion serves as a studio keyboard player for Aerosmith, and other musicians.

David R. Liu is the Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare, vice-chair of the faculty at the Broad Institute of MIT and Harvard, the Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University, and a Howard Hughes Medical Institute (HHMI) investigator. Liu's research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing—the first general method to perform precision gene editing without double-stranded breaks, and a Science 2017 Breakthrough of the Year finalist—as well as prime editing, PACE, and DNA-templated synthesis are four examples of technologies pioneered in his laboratory. These technologies are used by thousands of labs around the world and have enabled the study and potential treatment of many genetic diseases. FDA recently cleared the first base editing IND, allowing patients to receive the first base editing therapies in U.S. clinical trials.

Liu graduated first in his class at Harvard College in 1994. During his doctoral research at UC Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his PhD in 1999 and became assistant professor of chemistry and chemical biology at Harvard University in the same year. He was promoted to associate professor in 2003 and to full professor in 2005. Liu became a Howard Hughes Medical Institute investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. In 2016 he became a Core Institute Member and Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, and Director of the Chemical Biology and Therapeutics Science Program.

Liu has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. He is the 2022 King Faisal Prize Laureate in Medicine. He has earned several University-wide distinctions for teaching at Harvard, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College Professorship. Liu has published more than 225 papers and is the inventor on more than 90 issued U.S. patents. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society David Perlman Award, ACS Chemical Biology Award, the American Chemical Society Pure Chemistry Award, the Arthur Cope Young Scholar Award, the NIH Marshall Nirenberg Lecturer, and awards from the Sloan Foundation, Beckman Foundation, NSF CAREER Program, and Searle Scholars Program. In 2016 and 2020 he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and was named one of Nature's 10 researchers in world and to the Foreign Policy Leading Global Thinkers in 2017. He is the founder or co-founder of several biotechnology and therapeutics companies, including Beam Therapeutics, Prime Medicine, Editas Medicine, Pairwise Plants, Exo Therapeutics, Chroma Medicine, and Resonance Medicine.

D.A. Wallach is a venture capital investor and an acclaimed recording artist who Fast Company named one of the 100 Most Creative People in Business. While an undergraduate at Harvard, D.A. studied with professor Henry Louis Gates, Jr., and received the Andrew Ramroop and Alain Locke prizes as the top graduate in his department. Prior to leaving school, Kanye West and Pharrell Williams discovered D.A.'s band Chester French, and Williams signed the group to Interscope Records, where they released two full-length albums. He has toured with Lady Gaga, Weezer, and Blink 182, performed on TV Shows including Jimmy Kimmel Live and Late Night with Jimmy Fallon, and appeared in Rolling Stone and Vogue.

In 2011, D.A. stopped touring in order to focus on his other passion, investing. He has since built a parallel career as a venture capitalist, backing a series of industry-defining technology companies including Spotify, SpaceX, Ripple, The Boring Company, and Memphis Meats. Since 2015, D.A. has focused on biotechnology and healthcare, seeking to reinvent medicine through breakthrough start-ups like Beam, Glympse, Doctor on Demand, Devoted Health, and Neuralink. As co-founder and General Partner of Time BioVentures, he brings this experience to a new generation of talented entrepreneurs in the life sciences.

Outside of work, D.A. appeared as an actor in the film La La Land, which received 14 Academy Award nominations. He publishes essays on a range of topics on his website www.dawallach.com, and is the co-founder of the non-profit Franca Fund for preventive genomics and an advisory board member of No Patient Left Behind.

Rochelle P. Walensky, MD, MPH, is the 19th Director of the Centers for Disease Control and Prevention and the ninth Administrator of the Agency for Toxic Substances and Disease Registry. She is an influential scholar whose pioneering research has helped advance the national and global response to HIV/AIDS. Dr. Walensky is also a well-respected expert on the value of testing and treatment of deadly viruses.

Dr. Walensky served as Chief of the Division of Infectious Diseases at Massachusetts General Hospital from 2017-2020 and Professor of Medicine at Harvard Medical School from 2012-2020. She served on the frontline of the COVID-19 pandemic and conducted research on vaccine delivery and strategies to reach underserved communities.

Dr. Walensky is recognized internationally for her work to improve HIV screening and care in South Africa and nationally recognized for motivating health policy and informing clinical trial design and evaluation in a variety of settings.

She is a past Chair of the Office of AIDS Research Advisory Council at the National Institutes of Health, Chair-elect of the HIV Medical Association, and previously served as an advisor to both the World Health Organization and the Joint United Nations Programme on HIV/AIDS.

Originally from Maryland, Dr. Walensky received her Bachelor of Arts from Washington University in St. Louis, her Doctor of Medicine from the Johns Hopkins School of Medicine, and her Masters in Public Health from the Harvard School of Public Health.

John Sculley is the former Pepsi-Cola Co CEO during which time Pepsi became the largest selling consumer packaged group product in America. Later recruited to Apple by Steve Jobs to become Apple CEO, a position he held for 10 years. When Sculley left Apple revenues had grown over 1000 percent and Apple was the largest selling PC product in the world. Post Apple, John Sculley became an investor & mentor to many transformational entrepreneur CEOs. MetroPCS, one of the first digital wireless services, Intralinks, the first B2B Internet data services. Zeta Global, now one of the largest AI personalized marketing platforms.

Ten years ago, Bob Metcalfe, the inventor of Ethernet, said to John, "As we get older people like us should reinvent ourselves." As I thought about the idea of reinventing myself, I was reminded of a moment back in early 1983 when I was with Steve Jobs and Bill Gates late one evening in the Macintosh engineering lab. Steve and Bill were talking about how they were going to change the world one person at a time. Bill had invented shrink wrap software and Steve had his dream for the Macintosh that he called a "bicycle for the mind", a personal computer designed for non-technical people and easy to use and be able to do amazing creative tasks. Steve Jobs and Bill Gates called their dreams a "Noble Cause" for the future of civilization.

Remembering this story decades later led me to choosing my "Noble Cause", to help adapt the next generation of digital technologies- e.g. cloud platforms, automation, sensors, AI data, and virtual telehealth to help new generations of entrepreneurs build amazing digital health companies that will change the world of health and wellness.

Some of the companies I have been involved in as either a mentor or investor: Rally Health, became one of the most successful consumer preventive care & wellness services. Misfit Wearables became one of the first successful wearables with built in tracking sensors for fitness. RxAdvance, became the first AI robotic process automation platform designed to revolutionize the pharmacy services industry. Zedsen, a revolutionary non-invasive blood glucose monitor for diabetics. This same non-invasive electric field technology also works for early detection of cancerous tumors. Celularity has become a next generation bio-tech cell therapy company that is also a major innovator with COVID-19 patient treatment therapies. On Demand Pharma, is a US based manufacturer of generic prescription drugs using innovative pharmacology to create the first US based company to manufacture generic prescription drugs using US sourced active pharmaceutical ingredients.

Brown University undergraduate. Wharton MBA. Ellis Island Medal of Honor 12 honorary PhD's. Frequent CNBC TV guest. Well known lecturer around the world at major universities and other venues, Co-Founder with the original Sesame Street creative team along with WGBH in Boston of 'Between-the-Lions' which produced 90 television programs designed to teach young children how to read. These television shows have been running on PBS for over 20 years.

John Sculley and his wife Diane Sculley, a general contractor, computer scientist and mathematician work together as managing partners at their family office, Sculley Advisors, and their Sculley Family Foundation.

DEEPAK CHOPRA™ MD, FACP, founder of The Chopra Foundation, a non-profit entity for research on well-being and humanitarianism, and Chopra Global, a modern-day health company at the intersection of science and spirituality, is a world-renowned pioneer in integrative medicine and personal transformation. Chopra is a Clinical Professor of Family Medicine and Public Health at the University of California, San Diego and serves as a senior scientist with Gallup Organization. He is the author of over 90 books translated into over forty-three languages, including numerous New York Times bestsellers. His 90th book and national bestseller, Metahuman: Unleashing Your Infinite Potential (Harmony Books), unlocks the secrets to moving beyond our present limitations to access a field of infinite possibilities. For the last thirty years, Chopra has been at the forefront of the meditation revolution and his latest book, Total Meditation (Harmony Books, September 22, 2020) helps to achieve new dimensions of stress-free living and joyful living. TIME magazine has described Dr. Chopra as "one of the top 100 heroes and icons of the century." www.deepakchopra.com

Owner and Chairman - Blank Family of Businesses

Perhaps best known as co-founder of The Home Depot, Arthur Blank is now widely recognized for his diverse businesses. He has been distinguished by Forbes as one of the World's 100 Greatest Living Business Minds 2017, Sports Business Journal's Executive of the Year 2018 and Sports Business Journal's one of the 50 Most Influential People in Sports 2016, 2017, and 2018.

In addition to the Blank Family Foundation, Blank's Family of Businesses includes the Atlanta Falcons and Atlanta United; the nationwide PGA TOUR Superstore; three ranches in Montana, Mountain Sky Guest Ranch, West Creek Ranch and Paradise Valley Ranch; and Mercedes-Benz Stadium, which hosted the 2019 Super Bowl and is home to the Falcons and Atlanta United.

Blank believes in the importance of making a difference - professionally and personally. In addition to the company's financial success, during his 23 years with The Home Depot the company donated more than $113 million to communities, while associates participated in hundreds of thousands of hours of volunteer time. Blank is applying the same business acumen and values in building his competitive, successful and community-oriented businesses today.

Blank is dedicated to his own giving back. Since 1995, the Arthur M. Blank Family Foundation has granted more than $560 million to support early childhood development, education, the arts, social causes, veteran-causes, and parks and greenspace. The foundation also leads giving programs for each of the for-profit businesses in Blank's portfolio. Through his Foundation and businesses, Blank has donated nearly $7 million to COVID-19 pandemic relief.

A native of Queens, N.Y., Blank received a B.S. Degree in Business Administration with Distinction from Babson College. Blank resides in Atlanta, Georgia and is the father of six children and has six grandchildren. Consistent with the way he approaches work and life, his favorite T-shirt appropriately reads, "There is no finish line."

Eric Mead is a performing artist who defies categorization. As an onstage travel guide, he conducts interactive tours of the fantastic—where imagination is king, laughter erupts at every turn, and everything you know about the world is called into question.

What separates Eric from his contemporaries are the larger ideas he brings into his performances. Eric insists that entertainment is the most powerful tool available for effective and meaningful communication. His magic, his humor, his play with the audience are all aimed at sharing his unique point of view, making deep emotional connections, and creating memories that last a lifetime.

Mead's creative credits include writing and producing two successful magic themed television series: "Magic Man" for Travel Channel in the US, and "Magic Asia" for AXN Network in Singapore. On Fox Family's hit series "Masters of Illusion," Eric was honored to be asked to appear twice in a single season. In his appearance on "Penn and Teller: Fool Us," Eric walked away with the coveted "Fool Us" trophy, and Penn Jillette said, "It was the best sleight of hand performance we've seen in four seasons of the show." Although he has played small roles in a number of documentaries and feature films, critics universally praised Mead's scene stealing turn in the film "The Aristocrats" with Robin Williams, Whoopi Goldberg, John Stewart and the Smothers Brothers.

Eric is also a writer, academic, and highly sought after keynote speaker. In 2018 The Academy of Magical Arts at The Magic Castle presented Eric with a special Performing Fellowship in recognition of his lifetime work as an ambassador of the conjuring arts to the general public. Eric is also Senior Fellow at the Conjuring Arts Research Center in New York City, where he is associate professor of performance design.

When not on the road, Eric makes his home in the mountains just outside of Aspen, Colorado, where he lives with his wife and daughter.

Dr. Cheryl Pegus is Walmart's executive vice president of Health & Wellness. In this role, Cheryl will develop Walmart's bold healthcare vision, leading Health & Wellness across the Walmart enterprise.

She joins Walmart from Cambia Health Solutions where she was president of consumer health solutions and chief medical officer. There she was responsible for clinical and consumer strategy to increase access to affordable, equitable care. She directed platform consumer solutions including Journi, clinical services, pharmacy, provider and medical management activities.

After working in private practice for several years as a cardiologist, Cheryl joined Pfizer where she focused on the development of clinical protocols and early disease management programs. She also served at Aetna, where her work supported a focus on wellness, women's health, health equity initiatives and predictive analytics. Cheryl served as the first chief medical officer at Walgreens.

Additionally, Cheryl is co-founder of A New Beat, an organization dedicated to improving the cardiovascular health and careers of women and under-represented minorities. She sits on the board of the American Heart Association and is the immediate past board chair for the Association of Black Cardiologists.

Cheryl received her bachelor's degree from Brandeis University. Her medical doctorate is from Weill Cornell Medical College, and she has a master's degree in Public Health from Columbia University Mailman School of Public Health.

Alexandra is co-founder and CEO of ARCHANGELS. She served as Wellness Expert for Prudential, and co-founded Eliza Corporation (acquired by HMS Holdings Corp: HMSY), Engage with Grace, and three other companies (all boot-strapped). Her belief that retail is the front line of health has evolved into an obsession with any 'last mile', and builds on her fierce beliefs that caregivers are our country's greatest asset and that we need to expand the definition of health to include life.

Alexandra takes an active role with the non-profits she feels are doing their best to change the world, including two she co-founded. She sits on the Board of Advisors for RAND Health, the Leadership Council for the Rosalynn Carter Institute for Caregiving, the Entrepreneurs Council for The United States of Care, the Board of Advisors for Open Notes, and Harvard Medical School's Executive Council of the Division of Sleep Medicine. She is a Governor appointed member of the Executive Committee for the Board of Directors for the Massachusetts Technology Collaborative, a member of the Board of Directors of the Coalition to Transform Advanced Care (C-TAC), a member of the Board of Advisors at EndWell, and has served as the Vice Chair of the Board of Trustees of Beth Israel Deaconess Medical Center (a Harvard Teaching Hospital). She also serves on the Board of Advisors for MassChallenge HealthTech, and the Board of Advisor's for Boston Children Hospital's IDHA (Innovation and Digital Health Accelerator). Alex was named to the first ever Care100 list in 2020, a Top Women in Healthcare's Entrepreneur of the Year by PR News, one of Disruptive Women in Health Care's Women to Watch, one of Boston Globe's Top 100 Women Leaders, and listed in Boston Business Journal's "40 Under 40". She is also an inventor on multiple patents.

Alex's background in the healthcare industry made her the ideal candidate to join Prudential Financial in exploring the unique and modern challenges (and opportunities) facing Americans in a film series called "The State of US." She has one hobby outside of her passion for revolutionizing health care, and her love of family and adventure…car racing.

Dr. Peter Lee is Corporate Vice President, Research and Incubations, at Microsoft. He leads Microsoft Research across its eight laboratories around the world. He also oversees several incubation teams for new research-powered lines of business, the largest of which today is Microsoft's growing healthcare and life sciences effort. Dr. Lee has extensive experience in managing fundamental research to commercial impact in a range of areas, spanning artificial intelligence, to quantum computing, to biotechnology, and more. Before joining Microsoft in 2010, he was at DARPA, where he established a new technology office that created operational capabilities in machine learning, data science, and computational social science. From 1987 to 2005 he was a Professor at Carnegie Mellon University, and from 2005 to 2008 the Head of the university's computer science department. Today, in addition to his management responsibilities, Dr. Lee speaks and writes widely on technology trends and policies. He is a member of the National Academy of Medicine. He serves on the Boards of Directors of the Allen Institute for Artificial Intelligence, the Brotman Baty Institute for Precision Medicine, and the Kaiser Permanente Bernard J. Tyson School of Medicine. In public service, Dr. Lee was a commissioner on President Obama's Commission on Enhancing National Cybersecurity and led several studies for both PCAST and the National Academies on the impact of federal research investments on economic growth. He has testified before both the US House Science and Technology Committee and the US Senate Commerce Committee.

Francis deSouza was appointed CEO of Illumina in 2016 and is responsible for directing all aspects of company strategy, planning, and operations. He initially joined the company as President in 2013, and led Illumina's business units and core functions responsible for envisioning, developing and producing the company's products.

Previously, deSouza served as President of Products and Services at Symantec Corporation, where he was responsible for driving the vision for the company's market-leading portfolio and served in a variety of executive roles. He joined Symantec through the acquisition of IMlogic, where he was co-founder and CEO.

Prior to joining IMlogic, deSouza was co-founder and CEO of Flash Communications, a provider of corporate instant messaging that was acquired by Microsoft. Following the acquisition, he joined Microsoft and led the team responsible for the development of the company's enterprise real-time collaboration offerings. Currently, he is a member of the board of directors for The Walt Disney Company.

Francis deSouza received a BS and MS in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.

Governor Charlie Baker was sworn in for a second term as the 72nd Governor of the Commonwealth of Massachusetts on January 3, 2019, after a first term focused on moving Massachusetts forward through bipartisan, results-driven leadership.

Governor Baker has used public private partnerships to spur economic development, reformed the state's regulatory environment, and delivered critical tax relief by doubling the Earned Income Tax Credit.

Ensuring Massachusetts continues to be a national leader in education, Governor Baker has made historic investments in K-12 education, increased support for vocational and technical schools, and expanded early college opportunities for high school students.

Governor Baker has put Massachusetts at the forefront of fighting the opioid and heroin epidemic, doubling spending on prevention, education, treatment, and recovery and signing two major bills that have served as models for other states.

Confronted with the challenges of rising energy costs and a changing climate, Governor Baker has taken nation-leading steps to diversify the Commonwealth's energy portfolio, safeguard residents, municipalities and businesses from the impacts of climate change, and secure progress toward greenhouse gas reduction targets.

Governor Baker has spearheaded long overdue reforms at the MBTA that have led to significant improvements to operations and finances, and put the T on track to spend more than $8 billion on infrastructure over the next five years to improve riders' experience.

Prior to his election, Governor Baker was a highly successful leader of complex business and government organizations, serving as a cabinet secretary to both Governor William Weld and Paul Cellucci, and leading Harvard Pilgrim Health Care, as CEO, from the brink of bankruptcy to one of the nation's highest ranked health care providers.

Raised in Needham, Governor Baker and his wife Lauren reside in Swampscott, and are the proud parents of their three children, Charlie, AJ, and Caroline.

In 2014, when her husband Robin Williams died from Lewy body disease (LBD), artist Susan Schneider Williams set out to raise awareness about this devastating yet little known brain disease. Since receiving her husband's diagnosis after his death, only apparent in autopsy, she has become a prominent advocate and voice for LBD and brain disease research.

Schneider Williams served on the board at the American Brain Foundation (ABF) from 2016 through 2021 where she served as Vice Chair and played a leading role in strategic development. She spearheaded the ABF's groundbreaking 2021 research award targeted at the discovery of an accurate method of diagnosing Lewy body dementia. This $3 million multi-year award was created in partnership with the Alzheimer's Association, the Michael J. Fox Foundation for Parkinson's Research and the American Academy of Neurology (AAN).

Schneider Williams participated in the 2020 released documentary film Robin's Wish, centered around Robin's final years and his experience with LBD. She developed the idea for an educational version of the film called SPARK, now available to help aid institutions in raising awareness and funds for solving LBD.

Schneider Williams authored the editorial, "The terrorist inside my husband's brain," for the American Academy of Neurology's Neurology Journal. To date it is the #1 most read article of all time in Neurology. She was presented with the American Brain Foundation's Commitment to Cures Award in 2016 in recognition of her advocacy. She has spoken at academic institutions and private research corporations.

Schneider Williams has also lobbied in Washington, DC with the AAN, Michael J. Fox Foundation, and others for better diagnostics, increased funding, and support for researchers, doctors and clinicians. She has become a leading spokesperson for Lewy body dementia appearing on national television including, The Today Show, Good Morning America and CBS This Morning.

Alongside her fine art career, Schneider Williams continues her advocacy work to help bridge understanding about this disease where she can.

Daniel Kraft is a Stanford and Harvard-trained physician-scientist, inventor, entrepreneur, and innovator and is serving as the Chair of the XPRIZE Pandemic Alliance Task Force. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has chaired the Medicine for Singularity University since its inception, and is founder and chair of Exponential Medicine, a program that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare. Following undergraduate degrees from Brown University and medical school at Stanford, Daniel was Board Certified in both Internal Medicine & Pediatrics after completing a Harvard residency at the Massachusetts General Hospital & Boston Children's Hospital, and fellowships in hematology, oncology, and bone marrow transplantation at Stanford.

Daniel is a member of the Kaufman Fellows Society (Class 13) and member of the Inaugural class of the Aspen Institute Health Innovators Fellowship

He is heavily involved in digital health, founded Digital.Health, and is on the board of Healthy.io and advises several digital health-related startups. He is also the inventor of the MarrowMiner, an FDA-approved device for the minimally invasive harvest of bone marrow and founded RegenMed Systems, a company developing technologies to enable adult stem cell-based regenerative therapies.

Daniel is an avid pilot and has served in the Massachusetts and California Air National Guard as an officer and flight surgeon with F-15 & F-16 fighter Squadrons. He has conducted research on aerospace medicine that was published with NASA, with whom he was a finalist for astronaut selection

Jill Sobule's work is at once deeply personal and socially conscious, seriously funny and derisively tragic. In a dozen albums spanning three decades of recording, the Denver-born songwriter/guitarist/singer has tackled such topics as the death penalty, anorexia nervosa, shoplifting, reproduction, the French Resistance, adolescent malaise, LGBTQ issues, and the Christian Right.

Her hits include "I Kissed A Girl"—the first openly gay-themed song ever to crack the Billboard Top 20—and the alt-rock anthem "Supermodel" featured in the film "Clueless". Sobule was one half of The Jill & Julia Show, providing music while actor Julia Sweeney contributes storytelling.

Jill is considered a pioneer in crowdfunding and is constantly exploring and creating new models for artists in an ever-changing music industry. Her latest record is "Nostalgia Kills", produced by Ben Lee and released on her own Pinko Records label. Jill's theater credits include a musical adaptation of the Broadway classic "Yentl", "Prozak and the Platypus", and "Times Square". Her latest, "F*ck 7th Grade", was postponed due to Covid, but was performed and filmed for for three days at a make-shift drive-in over the Summer. The musical is a finalist for the Lambda Literary awards in LGBTQ Drama category this June.

"Jill Sobule can claim her place among the stellar New York singer-songwriters of the last decade.Topical, funny and more than a little poignant ...grown-up music for an adolescent age." Jon Pareles, New York Times

Michelle A. Williams, SM '88, ScD '91, is Dean of the Faculty, Harvard T.H. Chan School of Public Health, and Angelopoulos Professor in Public Health and International Development, a joint faculty appointment at the Harvard Chan School and Harvard Kennedy School. She is an internationally renowned epidemiologist and public health scientist, an award-winning educator, and a widely recognized academic leader. Prior to becoming Dean, she was Professor and Chair of the Department of Epidemiology at the Harvard Chan School and Program Leader of the Population Health and Health Disparities Research Programs at Harvard's Clinical and Translational Sciences Center. Dean Williams previously had a distinguished career at the University of Washington School of Public Health. Her scientific work places special emphasis in the areas of reproductive, perinatal, pediatric, and molecular epidemiology. Dean Williams has published over 450 scientific articles. She was elected to the National Academy of Medicine in 2016. The Dean has a master's in civil engineering from Tufts University and master's and doctoral degrees in epidemiology from the Harvard Chan School.

David explores new ways of improving human health and wellbeing through the air we breathe, with ramifications to how we eat, and regenerate life on the planet. His scientific research, as well as his inventions, startups, and creative spaces in France and the USA, have led to the discovery of airway hygiene and the new consumer health platform FEND. David was Professor of the Practice of Bioengineering at Harvard University in the School of Engineering & Applied Sciences from 2001 to 2019, and transitioned to Associate in 2019 to lead the startup of FEND, support the startup of the nonprofit Next Breath, and open the new Cambridge-based restaurant with Chef Nadia Michaud, Senses, where the commitment to organic regenerative food parallels the commitment of David's future-of-food company Incredible Foods. David has received many international honors and awards, is a member of the National Academy of Engineering in the USA and in France, a member of the National Institute of Inventors, and a Chevalier of the Arts & Letters by the French Ministry of Culture. His recent book Creating Things That Matter (Holt 2018) won a 2018 Nautilus Book of the Year Award.

Philanthropist Alice L. Walton is committed to increasing access to arts, improving education, enhancing health and advancing economic opportunity for all. Alice is dedicated to promoting diversity and access in all of her philanthropic work.

She founded Crystal Bridges Museum of American Art in Bentonville, Arkansas in 2011 and serves as chairperson of the museum's Board of Directors. She is a member of the Walton Family Foundation and founder of the Alice L. Walton Foundation.

In 2020, Crystal Bridges Museum of American Art opened a satellite location, the Momentary, focusing on contemporary visual and performing arts. These two institutions share a mission of providing access for all to world-class art and to date, Crystal Bridges has welcomed more than 5.6 million visitors from around the globe. Admission to both non-profit organizations is free for everyone.

Creating Access

Alice's philanthropic vision and commitment to increasing access to outstanding works of American Art extends to communities across the country. In 2017 she founded Art Bridges, a non-profit foundation that partners with institutions of all sizes to provide greater access to American art through projects that deeply engage communities.

In addition to her focus on access to the arts, Alice recently announced the formation of the Whole Health Institute and the development of the Whole Health School of Medicine and Health Sciences. Based in Bentonville, the organizations will drive radical transformation in healthcare delivery with the ultimate goal of making whole health and well-being affordable and accessible nationwide.

Jennifer L. Garrison, PhD, is Founder and Director of the Global Consortium for Female Reproductive Longevity & Equality (GCRLE) and an Assistant Professor at the Buck Institute for Research on Aging, the first independent biomedical research institute dedicated solely to understanding aging and age-related disease. She also holds appointments in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco (UCSF) and the Leonard Davis School of Gerontology at the University of Southern California (USC). She is a passionate advocate for women's health and is pioneering a new movement to advance science focused on female reproductive aging with the ultimate goal of ending menopause. This initiative, by focusing research on understanding how and why women go through reproductive decline in mid-life, has the potential to dramatically and significantly improve the health and well-being of women worldwide. Her own lab studies how coordinated communication between tissues sets up a delicate balance across organs - and how changes in signaling between the brain and the rest of the body leads to systemic aging. She wants to understand the complex interactions between the ovary and brain during middle-age to find the neuronal factors that lead to infertility and menopause.

Dr. Garrison received her Bachelor of Arts degree in Molecular Cell Biology from the University of California Berkeley then completed her PhD at UCSF in Chemistry and Chemical Biology where she was a National Science Foundation Fellow and an ARCS Scholar, then was a Helen Hay Whitney Foundation Postdoctoral Fellow at the Rockefeller University. She was named an Alfred P. Sloan Foundation Neuroscience Research Fellow and an Allen Institute for Brain Science Next Generation Leader and is the recipient of a Pathway to Independence Award and a Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators from the National Institutes of Health, a Glenn Medical Foundation Award for Research in Biological Mechanisms of Aging, and a Junior Faculty Award from the American Federation of Aging Research.

Louie Schwartzberg is an award-winning cinematographer, director, and producer who has spent his notable career providing breathtaking imagery using his time-lapse, high-speed, and macro cinematography techniques. Schwartzberg is a visual artist who breaks barriers, connects with audiences, and tells stories that celebrate life and reveal the mysteries and wisdom of nature, people, and places.

Louie's theatrical releases include the 3D IMAX film Mysteries of the Unseen World with National Geographic, narrated by Forest Whitaker; Wings of Life for Disneynature, narrated by Meryl Streep, and Americas Heart and Soul for Walt Disney Studios. Louie has also directed the Soarin' Around the World; the most popular motion simulator ride film now playing at Disney Theme Parks globally.

Louie has also directed 3 seasons of Moving Art, which are now streaming on Netflix. The series has obtained great reviews from both critics and audience members alike. Also featured on Netflix, is Fantastic Fungi, narrated by Brie Larson. The film opened in local theaters throughout the US and rated 100% on Rotten Tomatoes.

Schwartzberg's Visual Healing is an offering immersive nature films that seamlessly bring nature and music together to deliver positive physical, emotional, and psychological benefits in healthcare and hospitality. The Visual Healing program is used to transform spaces into life-like natural environments.

In 2022, Schwartzberg plans to release his next feature film, Gratitude Revealed. A journey forty years in the making, where the audience will uncover the many facets of gratitude and see their practical application in the everyday lives of Louie's subjects.

For Schwartzberg, the greatest satisfaction is creating works that inspire audiences to celebrate Life and protect what we love.

Dr. James Allison is the Regental Professor and Chair of the Department of Immunology, Vice President of Immunobiology, Executive Director of Immunotherapy Platform, Director of the Parker Institute for Cancer Research, Deputy Director for David H. Koch Center for Applied Research for Genitourinary Cancers, the Olga Keith Wiess Distinguished University Chair of Cancer Research. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation." Among his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents energy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-Debakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system to eradicate cancer.

Dr. Sharma is a nationally and internationally renowned physician scientist whose research work is focused on investigating mechanisms and pathways within the immune system that facilitate tumor rejection or elicit resistance to immune checkpoint therapy. She is a Professor in the departments of Genitourinary Medical Oncology and Immunology, and the T.C. and Jeanette D. Hsu Endowed Chair in Cell Biology, at MD Anderson Cancer Center. She is also the inaugural Scientific Director for the Immunotherapy Platform and the Co-Director of Parker Institute for Cancer Immunotherapy at MD Anderson Cancer Center. She is a member of the American Society for Clinical Investigation (ASCI). She received the Emil Frei III Award for Excellence in Translational Research in 2016, the Coley Award for Distinguished Research for Tumor Immunology in 2018, the Women in Science with Excellence (WISE) award in 2020, the Heath Memorial Award in 2021 and the Randall Prize for Excellence in Cancer Research in 2021.

In 2006, Dr. Sharma designed and conducted the first neoadjuvant (pre-surgical) trial, also known as a window-of-opportunity trial, with immune checkpoint therapy (anti- CTLA-4, ipilimumab), which allowed her to establish safety of the neoadjuvant approach for immune checkpoint therapy as well as provide tumor tissues for translational research studies. She identified the ICOS/ICOSL pathway as a novel target for cancer immunotherapy strategies. The neoadjuvant clinical trial in 2006 was also the first trial with immune checkpoint therapy in patients with bladder cancer. The clinical data indicated that 25% of patients had significant anti-tumor responses with pathologic complete responses. These data led Dr. Sharma to conduct additional clinical trials with immune checkpoint therapy (anti-PD-1, nivolumab) for patients with bladder cancer, which enabled FDA-approval of nivolumab as treatment for patients with metastatic bladder cancer. Dr. Sharma also led the clinical trials with immune checkpoint therapy (nivolumab and nivolumab plus ipilimumab) in patients with metastatic renal cell carcinoma (RCC), which led to FDA-approval of these agents as treatment for patients with RCC.

Dr. Sharma is the Principal Investigator for multiple immunotherapy clinical trials. Her studies have identified novel resistance mechanisms, including loss of interferon (IFN) signaling, VISTA+ immunosuppressive cells, increased EZH2 expression in T cells, TGF signaling in bone metastases, and CD73+ myeloid cells in GBM. Her work continues to drive the development of immunotherapy strategies for the treatment of cancer patients.

Dr. Sharma holds a Ph.D. in immunology and an M.D. from Pennsylvania State University. She completed her clinical residency at New York Hospital, Cornell Medical Center in New York, and her clinical fellowship was completed at the Memorial Sloan- Kettering Cancer Center.

Dr. Klausner is currently founder and Chief Scientist of Altos Labs and founder and Chairman of Lyell Immunopharma, Inc. He is President of the Milky Way Research Foundation and founder and Managing Partner of Milky Way Investments. He was founder and Director of Juno Therapeutics and founder and Director of GRAIL. He is Chairman of Sonoma Biotherapeutics. Co Founder and Chairman of Lifemine Therapeutics. He is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina Corporation. Previously, he was Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr. Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. Dr. Klausner served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development as well as a past president of the American Society of Clinical Investigation. He has served in senior advisory roles to the US, Norwegian, Qatari and Indian governments.

More specific to his own research accomplishments, Dr. Klausner has provided valuable mechanistic insights into cellular processes such as intracellular trafficking, translation, and protein assembly. He has also contributed to the understanding of posttranslational gene regulation mechanisms through his study of iron metabolism. Furthermore, his investigations into the von Hippel-Lindau (VHL) protein has led to further classification of the protein's tumor suppressive function in the context of renal cell carcinoma. His discovery of the T Cell Zeta chain and how T cells are activated was the basic science breakthrough that lead to successful cell- based CAR-T cancer therapy. Throughout his career, Dr. Klausner has consistently worked to apply the principles of science and technology to address the global cancer burden.

Dr. Klausner is well known for his work in cell and molecular biology, immunology and human genetics, and has been the author of more than 300 scientific articles and several books, in addition to receiving numerous awards, honorary degrees and other honors. He has served as an Advisor to the Presidents of the Academies for counterterrorism, and Liaison to the White House Office of Science & Technology Policy. He oversaw the writing of The National Science Education Standards, the first such standards for US Science Education. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

Sumbul Desai, MD serves as Vice President of Health at Apple, overseeing health initiatives including clinical product development, medical research, and innovative clinical partnerships. She also leads the regulatory and quality teams at Apple. Apple is also working with the best in the medical field, including Harvard T.H. Chan School of Public Health, the American Heart Association, Brigham and Women's Hospital and Johns Hopkins University, to conduct landmark health studies and advance discovery with the ResearchKit and CareKit platforms. Apple recently launched its Health Sharing and Walking Steadiness features, adding to the many consumer health tools available on Apple Watch and iPhone including ECG, Irregular Heart Rhythm, Cycle Tracking and Hearing Health.

Dr. Desai recently served as Vice Chair of Strategy and Innovation in the Department of Medicine at Stanford Medicine, as well as Associate Chief Medical Officer at Stanford Healthcare. She also serves as Clinical Associate Professor in the Department of Medicine at Stanford School of Medicine.

Dean Ornish, M.D., is the founder and president of the non-profit Preventive Medicine Research Institute and Clinical Professor of Medicine at UCSF and at UCSD. For over 40 years, he has directed clinical research demonstrating, for the first time, that comprehensive lifestyle changes may begin to reverse the progression of even severe coronary heart disease and also early-stage prostate cancer as well as other chronic diseases.

In 2010, CMS created a new Medicare benefit category to cover his reversing heart disease program, and it is now covering this when offered virtually via Zoom nationwide. He is currently directing the first randomized controlled trial to determine if these intensive lifestyle changes may stop or reverse the progression of early-stage Alzheimer's disease.

He is a #1 New York Times bestselling author of seven books. His three main-stage TED.com talks have been viewed by over seven million people.

He was appointed by President Clinton and also by President Obama to White House Advisory Commissions and by Governor Newsom and Maria Shriver to the Governor's Brain Trust on Alzheimer's Disease Prevention and Preparedness. He is also a member of The Lancet Oncology "Moonshot Commission" and has been a member of the board of directors of the San Francisco Food Bank.

The "Ornish diet" has been rated "#1 for Heart Health" by a panel of experts at U.S. News & World Report for 11 years from 2011-2022. He co-chaired the Google Health Advisory Council 2007-9.

He was recognized as "one of the 125 most extraordinary University of Texas alumni in the past 125 years;" a "National Public Health Hero" award from the University of California, Berkeley; the Beckmann Medal from the German Society for Prevention and Rehabilitation of Cardiovascular Diseases; by TIME magazine as a "TIME 100 Innovator;" by LIFE magazine as "one of the fifty most influential members of his generation;" by People magazine as "one of the most interesting people of the year;" and by Forbes magazine as "one of the world's seven most powerful teachers." www.ornish.com & www.PMRI.org & www.undoitbook.com

Ayub Khattak is co-founder and President and Chief Executive Officer of Cue Health, a health technology company whose mission is to enable personalized, proactive, and informed healthcare that empowers people to live their healthiest lives.

Ayub leads the Cue team of scientists, chemists, statisticians, engineers, and individuals experienced in FDA clearance of diagnostic products and more who are committed to creating a new standard of care in diagnostics, with the ability to bridge the physical to virtual care continuum and benefit everyone by keeping people healthy and productive.

Under Ayub's leadership, the company developed the Cue Health Monitoring System that enables fast, frequent, lab-quality diagnostics by anyone, anywhere. Cue's first commercially available product, the Cue COVID-19 Test Kit, provides highly accurate, lab-quality results directly to connected mobile smart devices in about 20 minutes. The Cue COVID-19 Test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use, without physician supervision or a prescription.

The idea for Cue was conceived in 2010 when Ayub and co-founder & Chief Product Officer Clint Sever recognized the problems with how the current health structure collects, communicates, and uses health data. They saw the opportunity to create a new model for care and started Cue to create tools that empower healthcare providers and consumers by increasing their access to actionable health data.

Ayub received a Bachelor of Science degree in mathematics from the University of California, Los Angeles.

Michael Polansky is the CEO of the Parker Group, the San Francisco-based organization that manages the business, investment, political and charitable interests of Silicon Valley entrepreneur and philanthropist Sean Parker. He is co-founder and Director at the Parker Institute for Cancer Immunotherapy, an unprecedented collaboration between the country's leading immunologists and cancer centers: Memorial Sloan Kettering Cancer Center, Stanford University, University of California, Los Angeles, University of California, San Francisco, the University of Pennsylvania, and the University of Texas MD Anderson Cancer Center. In addition, Michael co-founded ArsenalBio, a cell therapy company in San Francisco led by Ken Drazen and the Economic Innovation Group, a bipartisan public policy organization responsible for the development of the Investing in Opportunity Act. Michael serves on the boards of several technology companies and was previously an investor at Founders Fund where he focused on consumer internet and emerging technology. He is a graduate from Harvard University with a degree in Applied Mathematics and Computer Science.

Laurene Powell Jobs is founder and president of Emerson Collective. Using philanthropy, investing, storytelling, and convenings, Emerson Collective creates opportunities and develops innovative solutions to spur change in education, the environment, immigration, and health equity.

Laurene's commitment to renewing America's calcified social systems deepened over two decades ago with her work in education. In 1997, she founded College Track, a college completion program where she remains board chair, to address the alarming opportunity and achievement gaps among students. She is also cofounder and board chair of The XQ Institute, the nation's leading organization dedicated to transforming the American high school. In keeping with her belief in supporting journalism as a vital civic institution, Laurene is owner and board chair of The Atlantic.

Laurene serves on the Stanford University Board of Trustees and the boards of Chicago CRED, The Council on Foreign Relations, The Ford Foundation, and Elemental Excelerator, where she is board chair. In addition, she is a member of the National Academy of Arts and Sciences, and a recipient of Stanford Graduate School of Business' Ernest C. Arbuckle Award for managerial excellence and addressing the changing needs of society.

Laurene earned a B.A. in political science from the University of Pennsylvania College of Arts and Sciences and a B.S. in economics from The Wharton School. After graduating from Penn, she worked at Goldman Sachs before earning an MBA from Stanford Graduate School of Business.

Reed leads Emerson Collective's Health team. With a sole focus on oncology, his team accelerates the discovery and translation of cancer research to best improve and empower the lives of patients. To achieve this, Reed is an active philanthropist and venture investor. His philanthropic portfolio includes several competitive grant programs with major research entities in the U.S. and the U.K. Additionally, he is involved in the creation of a nonprofit organization to house altruistically donated patient genomic and clinical data to be made available to researchers across the United States, upon request. He graduated Stanford University with an honors degree in history and international security before achieving a master's degree in History. He is an avid traveler and distance runner.

As vice chair of the Clinton Foundation, Chelsea Clinton works alongside the Foundation's leadership and partners to improve lives and inspire emerging leaders across the United States and around the world. This includes the Foundation's early child initiative Too Small to Fail, which supports families with the resources they need to promote early brain and language development; and the Clinton Global Initiative University (CGI U), a global program that empowers student leaders to turn their ideas into action. A longtime public health advocate, Chelsea also serves on the board of the Clinton Health Access Initiative and uses her platform to increase awareness around issues such as vaccine hesitancy, childhood obesity, and health equity.

In addition to her Foundation work, Chelsea teaches at Columbia University's Mailman School of Public Health and has written several books for young readers, including the #1 New York Times bestseller She Persisted: 13 American Women Who Changed the World as well as She Persisted Around the World, She Persisted in Sports, She Persisted in Science, Start Now! You Can Make a Difference; Don't Let Them Disappear; and It's Your World: Get Informed, Get Inspired & Get Going. She is also the co-author of The Book of Gutsy Women and Grandma's Gardens with Secretary Hillary Rodham Clinton and of Governing Global Health: Who Runs the World and Why? with Devi Sridhar. Chelsea's podcast, In Fact with Chelsea Clinton, premiered in 2021 and is the co-founder of HiddenLight Productions.

Chelsea holds a Bachelor of Arts from Stanford, a Master of Public Health from Columbia's Mailman School of Public Health, and both a Master of Philosophy and a Doctorate in international relations from Oxford University. She lives with her husband Marc, their children Charlotte, Aidan and Jasper, and dog Soren in New York City.

Steve Connell is an actor, poet, motivator, and transformative entertainer whose live performances are as dynamic as the words he delivers. He has entertained at private performances for President Obama, Oprah Winfrey, Maya Angelou, and Norman Lear, amongst others. His work has been seen on ABC, HBO, MTV, and performed live at Sundance, TEDMED, Kennedy Center, and The White House. Corporate giants like Sony/Universal, Pioneer, Farmers and Gap Inc. are among the many companies amazed by Steve's ability to entertain & inform with immersive multimedia speeches & performances.

His most recent work, IMPERFECT, with Flexin' pioneer Drew Dollar and directed by Chisa Yamaguchi, examines our innate ability to inherit trauma but also resilience, and premiered with Lincoln Center's 2021 Restart Stages Series. His celebrated piece "We Are The Lions", developed in partnership with YWCA, has 10+ million views & was performed at the UN; his first short film, "the universe is chewing", co-starring Troian Bellisario was awarded a 2019 Best Shorts Humanitarian Award; and is hard at work developing his newest show, Unfinished, in reflection to the pivotal impact of the upcoming election. www.steveconnellcreates.com